A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)

Trial Profile

A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs CMB 305 (Primary)
  • Indications Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Synovate
  • Sponsors Immune Design
  • Most Recent Events

    • 01 Aug 2018 According to an Immune Design media release, company plans to present long-term follow-up data from its CMB305 monotherapy trial in soft tissue sarcoma patients at the European Society for Medical Oncology (ESMO) 2018 Congress in October.
    • 01 Aug 2018 According to an Immune Design media release, this trial is now open for enrollment in the U.S. to patients with synovial sarcoma.
    • 15 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top